ATLANTA (AP/WAOK) – The Food and Drug Administration is offering new survival hope to those suffering from late-stage metastatic breast cancer. The agency has given its blessing to a new drug that will be known by the brand name Kadcyla. In its approval announcement issued Friday, the FDA said the new drug is a therapy for women with HER2-positive breast cancer. Kadcyla is a combination of two drugs commonly known as Herceptin and the powerful chemotherapy drug called DM1. The treatment will be expensive. Kadcyla will cost nearly ten-thousand dollars each month and the regimen is generally just over nine months. Genentech, which developed the drug, says the company is working to get it out to patients “as soon as humanly possible.”